Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Company Deals

Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification

Fineline Cube Aug 29, 2023

A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...

Company

Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales

Fineline Cube Aug 29, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...

Company Drug

Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment

Fineline Cube Aug 29, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...

Company Drug

Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse

Fineline Cube Aug 29, 2023

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...

Company

Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access

Fineline Cube Aug 29, 2023

Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio...

Policy / Regulatory

China’s 9th National VBP Tender Round Targets CNS Drugs and Includes Oncology Therapies

Fineline Cube Aug 29, 2023

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Revises Drug Conditional Approval Procedures: Streamlined Processes and Requirements

Fineline Cube Aug 29, 2023

The National Medical Products Administration (NMPA) has released the “Drug Conditional Approval Filing Review and...

Company Deals

GenFleet Therapeutics and Verastem Oncology Ink Licensing Deal for RAS Pathway Cancer Therapies

Fineline Cube Aug 29, 2023

China-based GenFleet Therapeutics has entered into an exclusive licensing and early development agreement with US...

Company Drug

Boehringer Ingelheim Submits Three INDs for Survodutide Phase III Trials in China

Fineline Cube Aug 29, 2023

Germany-based Boehringer Ingelheim (BI) has announced the submission of three Investigational New Drug (IND) filings...

Company

Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...

Company Medical Device

Allurion’s Non-Invasive Weight-Loss Balloon Debuts at Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Aug 28, 2023

US-based Allurion’s (NYSE: ALUR) weight-loss intragastric balloon has been first applied in Shanghai Ruijin Hospital’s...

Company Drug

Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment

Fineline Cube Aug 28, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...

Company Policy / Regulatory

AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare

Fineline Cube Aug 28, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...

Company Drug

MSD Initiates Phase III Trial for PCSK9 Inhibitor MK-0616 in LDL Cholesterol Reduction

Fineline Cube Aug 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has commenced Phase III development for its experimental...

Company Deals

Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor

Fineline Cube Aug 28, 2023

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement...

Company Drug

Sandoz Receives FDA Clearance for First Biosimilar to Biogen’s Tysabri

Fineline Cube Aug 28, 2023

The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has received regulatory clearance from the US...

Posts pagination

1 … 445 446 447 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.